Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
March 16, 2023
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being here on our call covering the fourth quarter, the full year, and our business update. On the line with me are Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. David Clark, Trevi's Chief Medical Officer. Lisa and I will deliver some prepared remarks, and after that the 3 of us will take questions. For Trevi, 2022 was a year of transformation when it came to proving the wide-ranging usefulness of how our drug, Haduvio, works. Since both our IPF cough trial and our prurigo nodularis trial produced positive readouts, we found ourselves well positioned to determine the best way to grow the company on behalf of our stakeholders. Given how strong the cough data and IPF were, along with the absence of competitors in that area, we believe a robust and distinctive role in IPF therapy can be established by us. We further believe that the differentiated central and peripheral mechanism of our drug means we may be able to deliver therapy across a variety of chronic cough indications no matter what disease underlies them. So with those choices behind us and a strong capital raise completed in 2022, we are now buckled in and committed to executing our plans for the next stage of development. Now let me give an update on each program, beginning with our lead program in chronic cough and IPF. IPF is a severe end-of-life disease, and chronic cough represents a major source of morbidity, heavily affecting a patient's quality of life. Estimates suggest that as many as 85% of IPF patients deal with chronic coughing. As we get ready for our upcoming trials in this indication, there is a great deal we can learn from the development work taking place in refractory chronic cough. That said, there are also distinctive features of the IPF patient population tied not just to a possible impact on the underlying disease, but also to safety in this frail patient population, which we must bear in mind. During this next phase of development in our IPF chronic cough program, we intend to run 2 studies at the same time. The first is a Phase IIb dose-ranging trial examining 3 doses. The doses we intend to evaluate are 27, 54 and 108 milligrams BID. Drawing on data from the Phase II CANAL study, we have eliminated the highest dose, since it seems the efficacy showed up quite early in that trial and at the lower doses. Given how severely ill these patients are, grasping the minimally effective dose will matter. We are aiming for roughly 50 subjects per arm, for a total end in the study of 200, with dosing lasting about 6 weeks; we plan to run this study across multiple countries so that enrollment can be finished in a timely manner. Once the study begins, we will offer better guidance on enrollment time lines. At the same time, we are planning a Phase Ib respiratory physiology study. As you're probably aware, every drug in the opioid class carries a black box warning on its label about respiratory depression. Across all the studies we've conducted so far, that's not an issue that has turned up in our safety data. Still, given the lung impairment that IPF patients have, we believe it's a key question to investigate early on. Our plan is to conduct an inpatient trial in IPF patients, covering varying degrees of disease severity and escalating doses of Haduvio, to see whether any clinically significant effect on respiratory depression appears. These 2 studies are going to help us pin down the optimal dose or doses along with the patient population for our pivotal program; the respiratory physiology protocol has already gone to the FDA, and we're waiting on their feedback. Submissions in the U.K. and Europe are also being prepared to support these trials. The EU has a new regulatory pathway known as CTIS, which turned mandatory as of January 31, 2023. With this new pathway, reviews by the health authority and the ethics committees happen in parallel. Consequently, more information has to be supplied upfront in order to make the submission. In theory, this new pathway should make the review process more efficient, though there's limited data showing how implementation is actually going, and companies anticipate growing pains. So we'll keep you updated on our expected time lines, but I wanted you to know a new process is in play, which makes time lines hard to estimate. At the same time, our clinical operations team is getting these studies ready so that we can initiate once we have regulatory agreement on the protocol and an open IND; we expect to initiate both of these IPF studies in the second half of 2023, and once we begin the studies, we will provide guidance on the overall final design as well as the estimated timing for the trial. Beyond the preparations in IPF cough, we're also putting together a protocol for a Phase II refractory chronic cough study. That study will look a lot like the CANAL trial and will seek to establish proof-of-concept in refractory chronic cough. A lot of trials have been run in this condition, with just one mechanism having succeeded, the P2X3s. P2X3s act peripherally in the lung. Even so, we believe a significant opportunity remains for a mechanism that acts both centrally in the brain and peripherally in the lungs and could deliver strong and consistent efficacy across a broader set of RCC patients. Our cough data generated to date has continued to attract a lot of attention globally and has been presented at various respiratory meetings by KOLs in pulmonology. During the fourth quarter, Dr. Philip Molyneaux presented data at the British Thoracic Society meeting. We have also finalized a manuscript on the trial results and we'll be submitting it for publication shortly. A further presentation is scheduled for March 29 at the Annual German Pulmonology meeting. Then, on Monday, May 22, in Washington, D.C., we'll share additional CANAL results at the American Thoracic Society meeting. June 9 through 10 brings us to Reston, Virginia, for the American Cough Conference, where a presentation will cover our central and peripheral mechanism of action, explaining why it is unique and could matter broadly in cough. Worth noting, I believe, is that nearly every submission we made to these conferences was accepted for oral presentation. To my mind, that reflects how interested the medical community is in our program, and how significant the unmet medical need is that we're working to address. Our other program with ongoing work targets prurigo nodularis, or PN — a serious, debilitating condition marked by papules and nodules on the skin, along with relentless, severe itching. Back in June of last year, we reported positive results from the Phase IIb/III PRISM trial in PN as well. Statistical significance was reached on the primary endpoint and every key secondary endpoint. In the first quarter of 2023, we wrapped up the 1-year open-label extension study tied to PRISM.
Jennifer Good
executiveWe ought to get the results from that trial during Q2, and we'll get ready for an end of Phase II meeting with the FDA, which we anticipate holding before this year is out. In addition, we started a human abuse liability study during Q4 of last year. What we're trying to do with this study is compare how much abuse potential oral nalbuphine has versus butorphanol. At present, the injectable form of nalbuphine is unscheduled in the U.S. by the Drug Enforcement Agency, or DEA. Butorphanol carries a Schedule IV classification. This trial uses a randomized, double-blind, active and placebo-controlled 5-way crossover design. It runs in 2 parts, and the first part characterizes several butorphanol doses. A single butorphanol dose will be chosen for study in the protocol's second part, in order to establish the abuse potential of oral nalbuphine relative to whichever dose of butorphanol is selected. Right now the company is finishing Part 1 of the study and anticipates top line data from the full trial before 2023 ends. Things are busy at Trevi as we work to launch or run 4 separate studies and finish the open-label extension in PN. Getting this right matters a great deal, and David and his team are progressing nicely on every one of these. We'll announce the start of each study, with further details, as we kick off each one. Looking back at 2022, I feel enormously proud of how our team executed and of the favorable trial results across both of our lead indications. The trial data and the financings that followed have put us in a strong position to keep developing Haduvio not only for IPF chronic cough, but for other serious chronic cough conditions too, like RCC and cough in interstitial lung diseases. On PN, we're talking with possible partners about moving that program forward into the next stage of clinical development. Next steps for this program will be decided with help from the end of Phase II meeting with the FDA. I'll hand things over now to Lisa for a review of our financial results, and after that we'll take questions.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You can find the complete financial results for the 3- and 12-month periods that closed on December 31, 2022 in the press release we put out before this call, as well as in our 10-K, which we filed with the SEC today once the market had closed. I'll begin with how we did in the fourth quarter of 2022. During that quarter, our net loss came to $5.5 million, versus a net loss of $8.5 million in the comparable quarter of 2021. On a per-share basis, the net loss for the quarter was $0.06, compared with a net loss per share of $0.28 in the same quarter of 2021. R&D expenses totaled $4.3 million in the fourth quarter of 2022, down from $6.2 million in the equivalent quarter of 2021. That drop stemmed mainly from lower clinical trial costs, which reflected the fact that the blinded portions of both the PRISM and CANAL trials had wrapped up before the fourth quarter of 2022, partly offset by greater costs tied to the human abuse liability study that we kicked off in the fourth quarter of 2022. G&A expenses came in at $2.3 million in the fourth quarter of 2022, versus $2.1 million in the matching period of 2021. That rise was driven largely by greater legal fees connected to intellectual property filings, along with other professional fees. Other income, net, was $1.1 million in the fourth quarter of 2022, compared with other expense, net, of $300,000 in the matching period of 2021. This shift resulted mainly from higher interest income in 2022, thanks to investing the proceeds from our capital raises that closed during 2022, combined with interest rates that were higher than what was available in the fourth quarter of 2021. Now let me move to the results for the full year. For the year that ended December 31, 2022, our net loss was $29.2 million, versus a net loss of $33.9 million for 2021. Our net loss came in lower in 2022 because of reduced R&D expenses, which were $19.8 million across the full year 2022, compared with $23 million in 2021. That was offset by higher G&A expenses, which reached $10.1 million for the full year 2022, versus $9.5 million in 2021. Other income, net, was $0.7 million in 2022, compared with other expense, net, of $1.5 million in the matching period of 2021. What drove these shifts was mostly the same as what drove the fourth quarter changes I just walked through. A few remarks on cash and cash runway. In the fourth quarter of 2022, we brought in $3.1 million in gross proceeds from the underwriters' option for the greenshoe tied to our September offering; those funds, along with the money we raised earlier in the year, let us finish the year with cash, cash equivalents and marketable securities of $120.5 million. That leaves us with enough cash to keep operating into 2026, and that covers finishing the studies Jennifer described earlier today as well as repaying our term loan under the conditions it specifies. One last thing: I'd like to spend a moment on what has happened recently with SVB. As a lot of you are aware, the FDIC shut SVB down this past Friday and named itself receiver. SVB is our bank. That said, the bulk of our cash, cash equivalents and investments sat in custody accounts bearing our name at a different big financial institution, so our exposure was quite small. On Monday, the FDIC said every SVB deposit is protected, so at this point it's mostly an operational issue that we're working through; that brings our prepared remarks to a close. I'll hand the call back to the operator now for Q&A.
Leland Gershell
analystJennifer, I have a couple of questions, and they both really revolve around dosing. When you get into the abuse liability study, are you going to try to match the nalbuphine doses you're able to test against those in the dose-ranging study you're also kicking off? Or might you instead explore higher doses to check whether any undesirable effects show up? And in the same vein, for the RCC trial, if there's anything you can say right now, how could the doses in that RCC study compare with the doses you've tested thus far and the ones being evaluated in the IPF IIb?
Jennifer Good
executiveLeland, thanks for asking. David, since I went through that experience myself, I'll handle the first one on the house. Then, given that you're actively working on that protocol right now, why don't you cover the RCC dose. So, Leland, as far as the process and how it works, we'd already gone through all of that to determine the nalbuphine dose; that happened a year or 2 back, and essentially what you do is attempt to establish a maximum tolerated dose. So we kept escalating, and really, the guidance imposes a ceiling: once you reach 3x your effective dose in the market, you're permitted to stop, and that's where we managed to get. No MTD has been identified for nalbuphine. So I believe the exact dose is 480. David may refine that slightly. That dose, though, is going to be compared against the work underway with butorphanol, which likewise comes to essentially 3x what's available in the marketplace. So the doses are going to be pinned down, and it'll be roughly 3x what you observe in our clinical trials. Alright? Then, David, would you like to discuss RCC and how you're approaching the dosing?
David Clark
executiveYeah, exactly. And incidentally, you're absolutely correct that 486 is the highest dose that was used in the HAL study, like you mentioned, Jennifer. So indeed, we'll be aligning those doses. Regarding the RCC trial, which, as Jennifer described, will have a design quite close to CANAL — that 2-way crossover approach with roughly 60 subjects. The maximum dose we intend to evaluate in that setting would be 108 milligrams, given the favorable signal observed at the lower and intermediate doses in the CANAL trial within the IPF chronic cough group. Also, in the Phase IIb chronic cough IPF trial, which, as you're aware, is a dose-ranging study, the 3 doses chosen would be 27, 54 and 108, compared against placebos. So yes, we're planning to bring these doses together across the 2 programs.
Nathanael Charoensook
analystNat Charoensook here, filling in for Thomas Smith. To start off, what would need to fall into place before a Phase IIb dose-ranging trial in chronic cough with IPF can get underway — the one now slated for the second half of '23? And I've got a follow-up.
Jennifer Good
executiveI missed the opening portion of that — something about what has to happen before the Phase IIb can move forward? Was that your question?
Nathanael Charoensook
analystYes.
Jennifer Good
executiveAll right. So, here's the thing — David, could you walk us through the Phase IIb, and kind of explain how we move from where we are now to actually getting it started, given that you're the one overseeing that on a day-to-day basis?
David Clark
executiveRight. As Jennifer mentioned when introducing this, we'll provide exact guidance regarding the conduct phase for that trial after our planning is complete. For studies of this magnitude—200 subjects, as we're discussing—typically you'd target a recruitment period of roughly 12 months; that's something we can offer as a general benchmark. The main gating issue has actually been a modest postponement of that trial's start, largely caused by worldwide supply chain problems involving packaging materials, as it turns out; so our packaging materials were arriving considerably later than we'd intended. That's likely the biggest reason the study start shifted. Then the second element Jennifer referenced regarding trial conduct—the specifics of our projection for how long the study will run—the other significant contributor there is the new EU CTIS process you've probably heard about. So a new EU-wide clinical trial submission procedure now exists. It's mandatory as of this year rather than optional. And the anticipation is that this will delay many EU—that process will take as much as 3-plus months longer to get EU countries started because of this new procedure. So those are the 2 biggest factors.
Nathanael Charoensook
analystUnderstood, that helps a lot; and perhaps one more thing, so you're steering the complete dataset from the open-label extension study in the second quarter of '23. So what is it you intend to share? And what do you anticipate the data will show?
Jennifer Good
executiveYeah, this comes up frequently; and we have not yet resolved that. I believe we'd like to look at the data, kind of what does it reveal, what's in there. We will absolutely present it at a medical meeting. The dermatology community has a great deal of interest in it, no doubt. The way we address it, in a manner of speaking, from an IR standpoint, we still have to determine the optimal approach for that. So I'll hold off on that until we've seen the data and worked out the messaging from it; we'll determine the optimal approach for that.
Nathanael Charoensook
analystUnderstood. Then one final question, if you'll allow me. What do you anticipate for R&D and SG&A costs in '23 versus 2022?
Lisa Delfini
executiveMy expectation is that R&D costs will go up during 2023, since we'll be running all those studies that Jennifer mentioned, in contrast with 2022.
Jennifer Good
executiveWhile we're at it, let's cover G&A too.
Lisa Delfini
executiveMy expectation is that G&A will rise a little as well.
Sean Kim
analystI've got a question about the Phase Ib respiratory physiology study. Could you share a bit more detail regarding which dosing levels you plan to test in that trial? And beyond that, in what way might that shape the possible Phase III programs along with other trials in the pipeline?
Jennifer Good
executiveSure — David, please go ahead.
David Clark
executiveRight; so in all likelihood, we'll move to the 162 dose, which was the top dose reached through titration in the CANAL study. So it's probable that — titration will happen in a way comparable to what was done in CANAL. And apologies, what else were you asking about?
Jennifer Good
executiveAnd how to inform, David, that Phase III program, and what doses we use.
David Clark
executiveThese two studies genuinely need to be considered side by side. So when it comes to Phase III, the key question is how wide a group of IPF patients and their accompanying conditions we're dealing with — things like disordered sleep breathing, for instance sleep apnea. And we're including — the respiratory physiology study is what will truly give us that answer, because as we laid out in the opening remarks, that trial will enroll people with greater severity as well as those comorbidities that Phase II left out, which lets us make that determination for Phase III.
Sean Kim
analystAll right, and I just have one brief additional question regarding the Phase IIb dose ranging study. Given that enrollment is now expected to begin during the second half of '23, when should we anticipate seeing the top line readout?
Jennifer Good
executiveSure, Sean, I'd rather hold off on providing firm guidance about that until the study is actually underway. As David mentioned in his previous response, we are anticipating a recruitment period of approximately 12 months; dosing will last 6 months — pardon me, 6 weeks of dosing. So this isn't a lengthy study. However, I feel it's best to wait until we have it up and running, and at that point we'll offer improved timeline guidance. In the meantime, that lets you perform the calculation yourself and consider when you believe it might occur. Thank you for your report this week. I appreciate it.
Mayank Mamtani
analystThe amount of detail is much appreciated. Regarding the CANAL abstract getting accepted at PDS, I'd welcome your thoughts on that. Also, from what I understand, the PAciFy trials are also anticipated from Dr. Molyneaux, both of them involving morphine, following the test in IPF. Do you have any expectations you could share about relevant safety and efficacy data points that might matter for Haduvio? Then I have one more question after that.
Jennifer Good
executiveYes, that works, Mayank; as for our poster, I'm fully aware of its subject. I know they've been pulling and tugging at every different way of looking at the data. So David, I'm not certain. Do you know precisely what's being covered in it? It could be the anti-fibrotic data, though I can't say for sure. Please go ahead.
David Clark
executiveYeah. More analyses are coming, and they'll cover some end points that we hadn't shared previously — that's correct, that's what's shown there.
Jennifer Good
executiveRight, and Mayank, I believe your question concerned the morphine case in the U.K. involving Philip Molyneaux. Was that the subject you wanted me to address, and how I see it connecting to what we're doing in our program?
Mayank Mamtani
analystRight. Also, I believe some findings will be presented at APS regarding that.
Jennifer Good
executiveYeah, absolutely, that's wonderful. From where we sit, this trial has us enthusiastic since it adds further essential proof regarding the mechanism at play within this entire opioid pathway. Morphine comes with its own problems, obviously concerning respiratory depression plus the entire scheduling matter, Schedule II. Yet from our standpoint, we believe it simply keeps adding crucial scientific backing for the pathway. Thus, I believe it ought to succeed. Low doses of morphine are what they now employ; and based on what I've been told by numerous KOLs, it truly is the sole effective treatment for cough. That is partly what pulled us into this area. However, we believed that, to begin with, we act on 2 receptors, and we believed that given the improved safety profile and reduced abuse addiction profile of our drug, we might offer a far superior chronic choice. So I look forward to seeing it. My expectation is that it ought to succeed. And I don't feel intimidated by it due to all the points I just shared with you; plus obtaining a patent on that will be difficult for them. So probably some may prescribe it off label, yet additional obstacles exist when it comes to prescribing morphine in the current climate.
Mayank Mamtani
analystUnderstood. Then regarding those two trials — the Phase IIb IPF one and the RCC one — might you speak to the varying placebo responses that you're accounting for? And clearly, drawing on what you learned from CANAL, plus some of the dry run happening in P2X3 development programs?
Jennifer Good
executiveSure. And once more, as we set these trials out, we can address that in a bit more detail. What I'd say is that in IPF, which is perhaps somewhat further along here, we — there's a kind of accepted figure of about 25%. Ours came in a touch lower, approximately 23%. Yet if you look across all the trials conducted, that's a fairly solid estimate. In RCC, I believe we're collaborating with the leading experts in this area who hold all the data. David, I'm not sure whether you're familiar with the powering assumptions we're applying for placebo. You've been involved in that protocol.
David Clark
executiveYes, and I completely share your view regarding the IPF. When it comes to the IPF, even looking at trials done recently, placebo response rates have consistently stayed under 30%. With the RCC, what matters most is that the design is a 2-way crossover, the same as CANAL; in RCC trials of that kind, even ones conducted recently, placebo response has come in at roughly 20%. So that's not — the placebo response is quite distinct from what has shown up in RCC studies using a parallel group format over a longer duration.
Jennifer Good
executiveEveryone, we appreciate your joining us on this call today, and we look forward to speaking with some of you at the Needham Investor Conference, which takes place virtually from April 17 to the 20th. Thanks.
Operator
operatorThat brings us to the end of this call. We appreciate everyone joining us for today's presentation. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.